Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATF4 | P18848 | 10/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23332808 | 0.88 | ATF4 (0.76) | ATF4KMT2AMEN1ALDH1A1L3MBTL1 | |
| SCHEMBL23358914 | 0.86 | ATF4 (0.52) | ATF4 | |
| SCHEMBL30752511 | 0.85 | ATF4 (0.55) | ATF4KMT2AMEN1ALDH1A1L3MBTL1 | |
| SCHEMBL19555797 | 0.84 | ATF4 (0.65) | ATF4KMT2AMEN1KDM4ENPC1 | |
| SCHEMBL30335856 | 0.83 | ATF4 (0.55) | ATF4KMT2AMEN1KDM4EGAA | |
| SCHEMBL23773070 | 0.83 | ATF4 (0.57) | ATF4KMT2AMEN1KDM4EALDH1A1 | |
| SCHEMBL30729238 | 0.80 | ATF4 (0.48) | ATF4 | |
| SCHEMBL20722101 | 0.78 | ATF4 (0.75) | ATF4KMT2AMEN1ALDH1A1L3MBTL1 | |
| SCHEMBL29409118 | 0.76 | GAA (0.42) | ATF4KMT2AMEN1GAAALDH1A1 | |
| SCHEMBL30026217 | 0.76 | ATF4 (0.56) | ATF4GAAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250115563-A1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | CALICO LIFE SCIENCES LLC | 2025-04-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250115563-A1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | ATF4, ATF1, DDIT3 | ATF4 1/4885KMT2A 4320/4885MEN1 4714/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.